Last update: Dec. 8, 2017

Dulaglutide

Low Risk for breastfeeding


Moderately safe. Probably compatible.
Mild risk possible. Follow up recommended.
Read the Comment.

Long-acting agonist of the glucagon-like peptide receptor type 1 (GLP-1) that stimulates the endogenous secretion of insulin and decreases that of glucagon.
Used in type 2 diabetes in combination with other oral anti-diabetics, especially metformin.
Subcutaneous administration once a week.

There is risk of hypoglycaemia even in monotherapy.

Since the last update, we have not found published data on its excretion in breast milk.

Its pharmacokinetic data (very high molecular weight) make it very unlikely that it will be transferred to milk in significant quantities (Serrano 2014).

Due to its protein nature, it is inactivated in the gastrointestinal tract, not being absorbed, so its oral bioavailability is practically nil (Serrano 2014), except in premature babies and immediate neonatal period when there may be greater intestinal permeability.

Diet, exercise and breastfeeding improve blood glucose levels.

Alternatives

Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Tradenames

Main tradenames from several countries containing Dulaglutide in its composition:

Pharmacokinetics

Variable Value Unit
Bioavailability 0 %
Molecular weight 59.670 daltons
VD 0,27 l/Kg
Tmax 48 (24 - 72) hours
T1/2 120 hours

References

  1. EMA. Dulaglutide. Drug Summary. 2017 Full text (in our servers)
  2. EMA. Dulaglutida. Ficha técnica. 2017 Full text (in our servers)
  3. Serrano Aguayo P, García de Quirós Muñoz JM, Bretón Lesmes I, Cózar León MV. Tratamiento de enfermedades endocrinológicas durante la lactancia. [Endocrinologic diseases management during breastfeeding.] Med Clin (Barc). 2015 Abstract

Total visits

781

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine from United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM